# Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy

> **NCT00056238** · PHASE2 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 30 (—)

## Conditions studied

- Stroke
- Neurologic Diseases, General

## Interventions

- **DRUG:** NC-758 (Anti amyloidotic [Aß] agent)

## Key facts

- **NCT ID:** NCT00056238
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056238, "Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00056238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*